Abstract:Abstract Background Drug-drug interactions (DDIs) are a major concern in patients’ medication. It’s unfeasible to identify all potential DDIs using experimental methods which are time-consuming and expensive. Computational methods provide an effective strategy, however, facing challenges due to the lack of experimentally verified negative samples. Results To address this problem, we propose a novel positive-unlabeled learning method named DDI-PULearn for large-scale drug-drug-interaction predictions. DDI-PULearn first generates seeds of reliable negatives via OCSVM (one-class support vector machine) under a high-recall constraint and via the cosine-similarity based KNN (k-nearest neighbors) as well. Then trained with all the labeled positives (i.e., the validated DDIs) and the generated seed negatives, DDI-PULearn employs an iterative SVM to identify a set of entire reliable negatives from the unlabeled samples (i.e., the unobserved DDIs). Following that, DDI-PULearn represents all the labeled positives and the identified negatives as vectors of abundant drug properties by a similarity-based method. Finally, DDI-PULearn transforms these vectors into a lower-dimensional space via PCA (principal component analysis) and utilizes the compressed vectors as input for binary classifications. The performance of DDI-PULearn is evaluated on simulative prediction for 149,878 possible interactions between 548 drugs, comparing with two baseline methods and five state-of-the-art methods. Related experiment results show that the proposed method for the representation of DDIs characterizes them accurately. DDI-PULearn achieves superior performance owing to the identified reliable negatives, outperforming all other methods significantly. In addition, the predicted novel DDIs suggest that DDI-PULearn is capable to identify novel DDIs. Conclusions The results demonstrate that positive-unlabeled learning paves a new way to tackle the problem caused by the lack of experimentally verified negatives in the computational prediction of DDIs.

ZeroDDI: A Zero-Shot Drug-Drug Interaction Event Prediction Method with Semantic Enhanced Learning and Dual-Modal Uniform Alignment

Learning to Describe for Predicting Zero-shot Drug-Drug Interactions

DSN-DDI: an accurate and generalized framework for drug–drug interaction prediction by dual-view representation learning

META-DDIE: Predicting Drug-Drug Interaction Events with Few-Shot Learning

Deep learning for drug‐drug interaction prediction: A comprehensive review

DDI-PULearn: a positive-unlabeled learning method for large-scale prediction of drug-drug interactions

Predicting drug-drug interactions using multi-modal deep auto-encoders based network embedding and positive-unlabeled learning

FSRM-DDIE : few-shot learning methods based on relation metrics for the prediction of drug-drug interaction events

SSF-DDI: a deep learning method utilizing drug sequence and substructure features for drug–drug interaction prediction

DSIL-DDI: A Domain-Invariant Substructure Interaction Learning for Generalizable Drug–Drug Interaction Prediction

DeSIDE-DDI: interpretable prediction of drug-drug interactions using drug-induced gene expressions

TP-DDI: A Two-Pathway Deep Neural Network for Drug–Drug Interaction Prediction

R2-DDI: relation-aware feature refinement for drug-drug interaction prediction

AttentionDDI: Siamese attention-based deep learning method for drug–drug interaction predictions

MASMDDI: multi-layer adaptive soft-mask graph neural network for drug-drug interaction prediction

Multitype drug interaction prediction based on the deep fusion of drug features and topological relationships

Devil in the Tail: A Multi-Modal Framework for Drug-Drug Interaction Prediction in Long Tail Distinction

Learning size-adaptive molecular substructures for explainable drug–drug interaction prediction by substructure-aware graph neural network

SSI–DDI: substructure–substructure interactions for drug–drug interaction prediction

Multi-View Substructure Learning for Drug-Drug Interaction Prediction

Enhancing drug–drug interaction prediction by three-way decision and knowledge graph embedding